Join us for a discussion on the strategic considerations and requirements for securing patent and patent-like protection for cannabis-related inventions, including Utility Patents, Plant Patents and PVP. The panel will delve into the practical requirements for preparing and prosecuting each form of protection, including a discussion of deposit requirements (availability to 3rd parties and timing of deposits), data quality, scope (written description/enablement), and the dynamics for Plant Patent-Flexibility and data quality requirements
This program is eligible for 1 hours of General CLE credit in 60-minute states, and 1.2 hours of General CLE credit in 50-minute states. Credit hours are estimated and are subject to each state’s approval and credit rounding rules.
INCBA webinars are eligible for credit in the following states: AR, AL, AK, AZ, CA, CO, CT,DE, GA, HI, IL, IN, MN, MS, MO, NV, NH, NJ, NM, NY, NC, ND, OH, OR, PA, TN, TX, UT, VT, WV, and WI . Additional states may be available for credit upon self-application by attendees. States typically decide whether a program qualifies for MCLE credit in their jurisdiction 4-8 weeks after the program application is submitted. For many live events, credit approval is not received prior to the program.
INCBA on demand programs are eligible for credit in the following states: AR, AL, AK, AZ, CA, CO, CT,DE, GA, HI, IL, IN, MN, MS, MO, NV, NH, NJ, NM, NY, NC, ND, OH, OR, PA, TN, TX, UT, VT, WV, and WI . Additional states may be available for credit upon self-application by attendees. States typically decide whether a program qualifies for MCLE credit in their jurisdiction 4-8 weeks after the program application is submitted.
For current accreditation status, please select your jurisdiction below.
|Related Articles (432.4 KB)||Available after Purchase|
Nicole Grimm is a partner with McDonnell Boehnen Hulbert & Berghoff LLP (MBHB) and serves as Chair of the firm’s Cannabis Practice Group. She concentrates her practice on intellectual property matters, including patent procurement, counseling, inter partes review proceedings, and litigation. In particular, she prepares and prosecutes patent applications, prepares freedom to operate and patentability opinions, and handles global patent portfolios for biotechnology, pharmaceutical, and cannabis clients. She has also litigated cases involving patent, trade dress, and copyright infringement before U.S. District Courts.
Nicole co-founded the Cannabis Practice Group at MBHB to address the intellectual property needs of this emerging market. She frequently writes and speaks on issues related to intellectual property protection for cannabis businesses.
Nicole is a licensed attorney in Illinois and is admitted to practice before the U.S. Patent and Trademark Office. She earned her J.D. from the University of Maryland Francis King Carey School of Law, her M.S. in Biochemistry from the University of Colorado, and her B.A. in Biochemistry from McDaniel College.
While in law school, Nicole served as an intern for the Honorable Martin P. Welch, Chief Judge, 8th Judicial Circuit at the Baltimore City Circuit Court. Prior to law school, Nicole worked for The Johns Hopkins University as a research technologist.
Jon advises pharmaceutical companies and specializes in integrating regulatory and patent exclusivity strategies in order to maximize the value of his clients’ products. He has worked on several Orange Booklisted products. He works closely with his clients to develop and implement patent strategies, with a particular focus on late-stage clinical trial inventions that provide significant additional patent protection. He also has experience conducting patentability, invalidity, freedom-to-operate/non-infringement analyses, IPOs, and due diligence for acquisitions and sales. Jon has counseled clients in a variety of technologies including pharmaceutical formulations and methods of treatment based on clinical trials, new chemical entities, biotechnologies, companion diagnostics, purification processes, polymers, and food additives. He represents clients of all sizes, including startups, specialty pharma, and publicly traded companies. Jon knew he wanted to work with cutting edge pharmaceutical products, so he pursued in PhD in organic chemistry after earning his JD. Jon's doctoral research focused on the synthesis of multivalent ligands to study biological recognition processes in cancer. While pursuing his PhD, Jon was also in-house patent counsel at Montana State University’s Technology Transfer Office.
Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and author. He is the Founder and CEO of CReDo Science www.credo-science.com
Previously, he was Director of Research and Development of the International Cannabis and Cannabinoids Institute (ICCI) based in Prague, Czech Republic: https://www.icci.science. Medical Director of PHYTECS (2015-2017), a biotechnology company researching and developing innovative approaches targeting the human endocannabinoid system (http://www.phytecs.com), and from 2003-2014, he served as Senior Medical Advisor, medical monitor and study physician to GW Pharmaceuticals, United Kingdom for numerous Phase I-III clinical trials of Sativex® for alleviation of cancer pain unresponsive to optimized opioid treatment and initial studies of Epidiolex® for intractable epilepsy (https://www.gwpharm.com).
He graduated from the University of Pennsylvania (Psychology), and the University of Massachusetts Medical School, before residencies in Pediatrics in Phoenix, Arizona and in Child and Adult Neurology at the University of Washington in Seattle. He was a clinical neurologist in Missoula, Montana for 20 years in a practice with a strong chronic pain component. In 1995, he pursued a 3-month sabbatical doing ethnobotanical research with the Machiguenga people in Parque Nacional del Manu, Peru.
He has held faculty appointments in Pharmaceutical Sciences at the University of Montana, in Medicine at the University of Washington, and as visiting professor, Chinese Academy of Sciences, Harvard University, and Johns Hopkins University.
He is a Past-President of the International Cannabinoid Research Society and is former Chairman of the International Association for Cannabinoid Medicines. He serves on the Scientific Advisory Board for the American Botanical Council. He is author of Handbook of Psychotropic Herbs, co-editor of Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential, and author of The Last Sorcerer: Echoes of the Rainforest. He was founding editor of Journal of Cannabis Therapeutics, selections of which were published as books: Cannabis Therapeutics in HIV/AIDS, Women and Cannabis: Medicine, Science and Sociology, Cannabis: From Pariah to Prescription, and Handbook of Cannabis Therapeutics: From Bench to Bedside. He has also published numerous book chapters, and over fifty articles in neurology, pain management, cannabis, and ethnobotany. His research interests have included correlations of historical uses of cannabis to modern pharmacological mechanisms, phytopharmaceutical treatment of migraine and chronic pain, herbal synergy and phytocannabinoid/terpenoid, serotonergic and vanilloid interactions.
He has consulted or lectured on these topics in 44 US states and Canadian provinces and 44 countries on six continents.
Shahnam is a registered patent attorney who advises global pharmaceutical, agricultural, and other life science and technology companies on all aspects of patent portfolio development, analysis and appeals, as well as post-grant proceedings and intellectual property transactional activities. He has prepared and prosecuted more than 1,000 U.S. and international patent applications and, as a former patent examiner, provides customized approaches to his clients in a wide range of technologies, including chemistry, pharmaceuticals, pharmacology, biotechnology, medical diagnostics and cosmetic products.
He provides a full range of patent law services to clients, including infringement and validity studies, freedom-to-practice studies and design-around to help clients achieve their strategic and commercial goals. He has also appeared before the Patent Trial and Appeal Board in a number of proceedings on behalf of his clients.
As a Regulatory Affairs Certified (RAC) professional, Shahnam utilizes a strong understanding of the regulatory framework of cannabis and hemp-derived CBD products to advise clients on FDA regulatory matters, marketing and advertising strategies for drug and dietary supplement products.
Genetics & Bioscience
Original Program Date: 11/29/2020 - SKU INCBA112920GE
Please wait ...